Hypertriglyceridemia is common among patients infected with HIV and often requires treatment with a triglyceride-lowering medication, such as fenofibrate. Studies have shown that fenofibrate has the potential to increase serum creatinine, a phenomenon that seems to occur more in patients with baseline renal dysfunction or who are on medications that can affect renal hemodynamics. HIV-infected individuals are at an increased risk of developing renal problems and may be a target population for fenofibrate-induced increases in serum creatinine. The purpose of this report is to describe a case of an HIV-infected individual who experienced a considerable increase in serum creatinine after initiating fenofibrate, and to highlight this underreported yet important adverse effect. Additionally, we discuss the postulated mechanisms, relevant literature among HIV noninfected individuals, and potential risk factors.
SoRelleR. Vascular and lipid syndromes in selected HIV-infected patientsCirculation. 1998;98(9):829–830.
2.
HenryKMelroeHHuebschJ. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351(9112):1328.
3.
CarrASamarasKChisholmDJCooperDAPathogenesis of HIV-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 1998;351(9119):1881–1883.
4.
HenryKMelroeHHuebeschJ. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352(9133):1031–1032.
5.
PenzakSRChuckSK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000;32:111–123.
6.
DubéMPSprencherDHenryWK. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-Infected adults receiving antiretroviral therapy. Recommendations of the Adult ACTG Cardiovascular disease Focus group. Clin Infect Dis. 2000;31(5):1216–1224.
7.
CarrASamarasKThorisdottirA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–2099.
8.
PenzakSRChuckSK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs. 2002;2(2):91–106.
9.
SpositoACCaramelliBSartoriAMRamiresJAF. The lipoprotein in HIV infected patients. Braz J Infect Dis. 1997;1(6):275–283.
10.
GrunfeldCPangMDoerrlerW. Lipids, lipoproteins, triglycerides clearance, and cytokines in human immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–1052.
11.
ConstansJPellegrinJLPeuchantE. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24(6):416–420.
12.
ThomasJCLopes-VirellaMFDel BeneVE. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000;20(6):727–734.
13.
CaramelliBde BernocheCYSartoriAM. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis. 2001;5(6):332–338.
14.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
15.
de LuisDABachillerPAllerR.Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor [letter]. Nutrition. 2001;17(5):414–415.
16.
VictorGKravcikS. The effectiveness of anti-lipid therapy in protease inhibitor-induced hypertriglyceridemia [abstract no.B212]. Can J Infect Dis. 1999;10(suppl B):24B.
WinstonJDerayGHawkinsTSzczechLWyattCYoungB.Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47(11):1449–1457.
19.
Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
20.
MocroftAKirkOGatellJChronic renal failure among HIV-1-infected patients. AIDS. 2007;21(9):1119–1127.
21.
MocroftAKirkOReissP. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667–1678.
22.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39
(2 suppl):S1–S266.
23.
WilsonTWAlonso-GaliciaMRomanRJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31
(1 pt 2):225–231.
24.
AndreevEKoopmanMAriszL.A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?J Intern Med. 1999;246(3):247–252.
25.
MichalikLAuwerxJBergerJP. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev.2006;58(4):726–741.
26.
WilsonMWLayLTChowCK. Altered hepatic eicosanoid concentrations in rats treated with peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch Toxicol. 1995;69(7):491–497.
27.
KeechASimesRJBarterP. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
28.
GenestJFrohlichJSteinerG. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol. 2004;93(7):848–853.
29.
ACCORD Study Group, GinsbergHNElamMBLovatoLC. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
30.
BroedersNKnoopCAntoineM. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?Nephrol Dial Transplant. 2000;15(12):1993–1999.
31.
LipscombeJLewisGFCattranD. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55(1):39–44.
32.
RitterJLNabulsiS. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy. 2001;21(9):1145–1149.
GajdosMDzurikR. Fibrates and renal function. Clin Nephrol. 2003;60(1):65–66.
35.
HottelartCEl EsperNRoseF. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536–541.
36.
McQuadeCRGriegoJAndersonJPaiAB. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65(2):138–41.
37.
CoreshJSelvinEStevensLA. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.
38.
SzczechLAGangeSJvan der HorstC. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61(6):195–202.
39.
FranceschiniNNapravnikSEronJJJrSzczechLAFinnWF. Incidence and etiology of acute renal failure among ambulatory HIV infected patients. Kidney Int. 2005;67(4):1526–1531.
40.
WinstonJA. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010;17(1):19–25.
41.
WyattCMMorgelloSKatz-MalamedR. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428–34.
42.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
